Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

We recently compiled a list of the 10 Best Guru Stocks To Buy Now. In this article, we will have a look at where Roivant ...

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bluebird Bio (BLUE – Research Report), ...

Goldman Sachs analyst Chris Shibutani has maintained their bullish stance on ROIV stock, giving a Buy rating today. Chris Shibutani has given ...

On Thursday, Goldman Sachs maintained its Buy rating and $17.00 price target on shares of Roivant Sciences (NASDAQ:ROIV). The firm's positive stance comes after Roivant Sciences announced a ...

On Thursday, Goldman Sachs (NYSE:GS) maintained its Buy rating and $17.00 price target on shares of Roivant Sciences (NASDAQ:ROIV). The firm's positive stance comes after Roivant Sciences announced a ...

"This is another example of Roivant's ability to offer creative win-win collaborations. We are able to meet Organon's structural objectives and to create a transaction that is very attractive to both ...

H.C. Wainwright maintained a Buy rating on Roivant Sciences (NASDAQ:ROIV), with a consistent price target of $18.00. The firm's endorsement is grounded on a valuation model projecting a 6x ...

H.C. Wainwright maintained a Buy rating on Roivant Sciences (NASDAQ:ROIV), with a consistent price target of $18.00. The firm's endorsement is grounded on a valuation model projecting a 6x multiple on ...